These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 26563258)

  • 41. Cevipabulin (TTI-237): preclinical and clinical results for a novel antimicrotubule agent.
    Ayral-Kaloustian S; Zhang N; Beyer C
    Methods Find Exp Clin Pharmacol; 2009 Sep; 31(7):443-7. PubMed ID: 19907719
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeting mitosis for anti-cancer therapy.
    Sudakin V; Yen TJ
    BioDrugs; 2007; 21(4):225-33. PubMed ID: 17628120
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An update on the developing mitotic inhibitors for the treatment of non-small cell carcinoma.
    Sacco PC; Gridelli C
    Expert Opin Emerg Drugs; 2017 Sep; 22(3):213-222. PubMed ID: 28836854
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells.
    Giannakakou P; Gussio R; Nogales E; Downing KH; Zaharevitz D; Bollbuck B; Poy G; Sackett D; Nicolaou KC; Fojo T
    Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2904-9. PubMed ID: 10688884
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anticancer therapy with novel tubulin-interacting drugs.
    Kavallaris M; Verrills NM; Hill BT
    Drug Resist Updat; 2001 Dec; 4(6):392-401. PubMed ID: 12030786
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A microenvironment based model of antimitotic therapy of Gompertzian tumor growth.
    Kozusko F; Bourdeau M; Bajzer Z; Dingli D
    Bull Math Biol; 2007 Jul; 69(5):1691-708. PubMed ID: 17577604
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.
    Yardley DA
    Clin Breast Cancer; 2008 Dec; 8(6):487-92. PubMed ID: 19073502
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of antimitotic activity of herbal extracts using plant-based model systems and their cytotoxic potential against human colon carcinoma cells.
    Parmar MP; Waghela BN; Vaidya FU; Pathak C; Parmar DV
    J Cancer Res Ther; 2021; 17(6):1483-1490. PubMed ID: 34916382
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 17-beta-estradiol analog inhibits cell proliferation by induction of apoptosis in breast cell lines.
    Visagie MH; Birkholtz LM; Joubert AM
    Microsc Res Tech; 2014 Mar; 77(3):236-42. PubMed ID: 24449492
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New insights into Vinca alkaloids resistance mechanism and circumvention in lung cancer.
    Zhang Y; Yang SH; Guo XL
    Biomed Pharmacother; 2017 Dec; 96():659-666. PubMed ID: 29035832
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Microtubule dynamics as a target in oncology.
    Risinger AL; Giles FJ; Mooberry SL
    Cancer Treat Rev; 2009 May; 35(3):255-61. PubMed ID: 19117686
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Natural products as antimitotic agents.
    Dall'Acqua S
    Curr Top Med Chem; 2014; 14(20):2272-85. PubMed ID: 25434355
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Antitubulin agents].
    Dumontet C
    Bull Cancer; 2011 Nov; 98(11):1275-85. PubMed ID: 22023745
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discovery of thalicthuberine as a novel antimitotic agent from nature that disrupts microtubule dynamics and induces apoptosis in prostate cancer cells.
    Levrier C; Rockstroh A; Gabrielli B; Kavallaris M; Lehman M; Davis RA; Sadowski MC; Nelson CC
    Cell Cycle; 2018; 17(5):652-668. PubMed ID: 28749250
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Syringic acid from Tamarix aucheriana possesses antimitogenic and chemo-sensitizing activities in human colorectal cancer cells.
    Abaza MS; Al-Attiyah R; Bhardwaj R; Abbadi G; Koyippally M; Afzal M
    Pharm Biol; 2013 Sep; 51(9):1110-24. PubMed ID: 23745612
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC.
    Medema RH; Lin CC; Yang JC
    Clin Cancer Res; 2011 Oct; 17(20):6459-66. PubMed ID: 22003073
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synthesis and antimitotic activity of novel 2-methoxyestradiol analogs--Part II.
    Rao PN; Cessac JW; Boyd JW; Hanson AD; Shah J
    Steroids; 2008 Feb; 73(2):158-70. PubMed ID: 18155740
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A novel anti-microtubule agent with carbazole and benzohydrazide structures suppresses tumor cell growth in vivo.
    Ohira M; Iwasaki Y; Tanaka C; Kuroki M; Matsuo N; Kitamura T; Yukuhiro M; Morimoto H; Pang N; Liu B; Kiyono T; Amemiya M; Tanaka K; Yoshida K; Sugimoto N; Ohshima T; Fujita M
    Biochim Biophys Acta; 2015 Sep; 1850(9):1676-84. PubMed ID: 25960391
    [TBL] [Abstract][Full Text] [Related]  

  • 59. How do anti-mitotic drugs kill cancer cells?
    Gascoigne KE; Taylor SS
    J Cell Sci; 2009 Aug; 122(Pt 15):2579-85. PubMed ID: 19625502
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cell cycle-dependent cytotoxicity and mitotic spindle checkpoint dependency of investigational and approved antimitotic agents.
    Birk M; Bürkle A; Pekari K; Maier T; Schmidt M
    Int J Cancer; 2012 Feb; 130(4):798-807. PubMed ID: 21387302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.